There is insufficient in vivo evidence validating the therapeutic efficacy and safety of MIX in animal models of DKD and inadequate understanding of the molecular pathways modulated by these combined components, specifically through the TGF-β/Smads signaling pathway. Here, TGFB1 is linked to diabetic kidney disease.